NORTH CHICAGO, Illinois,
February 17, 2017 /PRNewswire/ --
The board of directors of AbbVie Inc. (NYSE: ABBV) has
authorized a $5 billion increase to
AbbVie's existing stock repurchase program.
Purchases may be made from time to time in management's
discretion. The stock repurchase authorization permits shares to be
repurchased in open market or private transactions, has no time
limit and may be discontinued at any time.
About AbbVie
AbbVie is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott Laboratories. The
company's mission is to use its expertise, dedicated people and
unique approach to innovation to develop and market advanced
therapies that address some of the world's most complex and serious
diseases. Together with its wholly-owned subsidiary, Pharmacyclics,
AbbVie employs approximately 30,000 people worldwide and markets
medicines in more than 170 countries. For further information on
the company and its people, portfolio and commitments, please visit
www.abbvie.com. Follow @abbvie on Twitter or view careers on our
Facebook or LinkedIn page.
CONTACT: Adelle Infante,
+1-(847) 938-8745, or Investors: Liz
Shea, +1-(847) 935-2211
This is a disclosure announcement from PR Newswire.